Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.

Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF.

Cell. 2019 Apr 18;177(3):556-571.e16. doi: 10.1016/j.cell.2019.02.005. Epub 2019 Apr 4.

PMID:
30955881
2.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ.

Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.

PMID:
30552023
3.

Immunotherapy for melanoma.

Cuevas LM, Daud AI.

Semin Cutan Med Surg. 2018 Jun;37(2):127-131. doi: 10.12788/j.sder.2018.028.

PMID:
30040090
4.

Melanocytic Neoplasms, Introduction.

Daud AI.

Semin Cutan Med Surg. 2018 Jun;37(2):87. doi: 10.12788/j.sder.2018.030. No abstract available.

PMID:
30040084
5.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
6.

A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.

Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF.

Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25.

7.

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma.

Daud AI.

Lancet Oncol. 2018 Jul;19(7):852-853. doi: 10.1016/S1470-2045(18)30353-X. Epub 2018 Jun 13. No abstract available.

PMID:
29908989
8.
9.

Revisiting RECIST: the case of treatment beyond progression.

Daud AI.

Lancet Oncol. 2018 Feb;19(2):157-159. doi: 10.1016/S1470-2045(18)30007-X. Epub 2018 Jan 18. No abstract available.

PMID:
29361472
10.

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.

Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI.

JCI Insight. 2017 Jul 20;2(14). pii: 93433. doi: 10.1172/jci.insight.93433. eCollection 2017 Jul 20.

12.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

13.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

14.

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.

Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI.

J Immunother Cancer. 2016 Sep 20;4:58. doi: 10.1186/s40425-016-0162-9. eCollection 2016.

15.

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD.

J Clin Invest. 2016 Sep 1;126(9):3447-52. doi: 10.1172/JCI87324. Epub 2016 Aug 15.

16.

Part II: Checkpoint inhibitors in cancer therapy.

Daud AI.

Immunotherapy. 2016 Jun;8(7):761-2. doi: 10.2217/imt-2014-0051. No abstract available.

17.

Part I: Checkpoint inhibitors in cancer therapy.

Daud AI.

Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051. No abstract available.

18.

Nivolumab plus ipilimumab in the treatment of advanced melanoma.

Tsai KK, Daud AI.

J Hematol Oncol. 2015 Oct 31;8:123. doi: 10.1186/s13045-015-0219-0.

19.

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI.

Br J Cancer. 2015 Apr 14;112(8):1326-31. doi: 10.1038/bjc.2014.541. Epub 2015 Mar 31.

20.

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.

Tsai KK, Daud AI.

Drugs. 2015 Apr;75(6):563-75. doi: 10.1007/s40265-015-0376-z. Review.

PMID:
25802230
21.

PD-1 and PD-L1 antibodies for melanoma.

Tsai KK, Zarzoso I, Daud AI.

Hum Vaccin Immunother. 2014;10(11):3111-6. doi: 10.4161/21645515.2014.983409. Review.

22.

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN.

J Clin Oncol. 2015 Mar 20;33(9):1060-6. doi: 10.1200/JCO.2014.57.5027. Epub 2015 Jan 20.

PMID:
25605849
23.

Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.

Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM.

JAMA Dermatol. 2014 Nov;150(11):1209-12. doi: 10.1001/jamadermatol.2014.838.

PMID:
25142409
24.

Combinatorial approach to treatment of melanoma.

Ashworth MT, Daud AI.

Hematol Oncol Clin North Am. 2014 Jun;28(3):601-12. doi: 10.1016/j.hoc.2014.03.002. Review.

PMID:
24880950
25.

Reply to M.-E. Percival et al and L.B. Saltz.

Daud AI.

J Clin Oncol. 2013 Jul 1;31(19):2515-6. No abstract available.

PMID:
23967490
26.

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19.

27.

Removing the unknown from the carcinoma of unknown primary.

Daud AI.

J Clin Oncol. 2013 Jan 10;31(2):174-5. doi: 10.1200/JCO.2012.45.7630. Epub 2012 Dec 10. No abstract available.

PMID:
23233703
28.

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.

29.

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI.

Br J Cancer. 2012 Jan 3;106(1):85-91. doi: 10.1038/bjc.2011.514. Epub 2011 Nov 29.

30.

BEAM trial: lighting the way ahead?

Daud AI.

J Clin Oncol. 2012 Jan 1;30(1):6-7. doi: 10.1200/JCO.2011.37.5832. Epub 2011 Nov 28. No abstract available.

PMID:
22124100
31.

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.

Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC.

Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.

32.

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

Munster PN, Daud AI.

Expert Opin Investig Drugs. 2011 Nov;20(11):1565-74. doi: 10.1517/13543784.2011.617740. Review.

PMID:
21985236
33.

An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor.

Ahronowitz IZ, Daud AI, Leong SP, Shue EH, Bastian BC, McCalmont TH, Yu SS.

J Cutan Pathol. 2011 Oct;38(10):801-7. doi: 10.1111/j.1600-0560.2011.01757.x. Epub 2011 Aug 23.

PMID:
21883364
34.

New horizons in melanoma treatment: targeting molecular pathways.

Soon CW, Algazi AP, Cha EN, Daud AI.

Ochsner J. 2010 Summer;10(2):93-8. No abstract available.

35.

NRAS-mutant melanoma: response to chemotherapy.

Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI.

Arch Dermatol. 2011 May;147(5):626-7. doi: 10.1001/archdermatol.2011.85. No abstract available.

PMID:
21576590
36.

Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.

Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV.

J Comput Assist Tomogr. 2011 Jan-Feb;35(1):86-90. doi: 10.1097/RCT.0b013e3181fce2cb.

37.

Treatment of cutaneous melanoma: current approaches and future prospects.

Algazi AP, Soon CW, Daud AI.

Cancer Manag Res. 2010 Aug 17;2:197-211. doi: 10.2147/CMR.S6073.

38.

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.

DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI.

Br J Cancer. 2010 Nov 9;103(10):1548-53. doi: 10.1038/sj.bjc.6605931. Epub 2010 Oct 5.

39.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK.

Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 2010 May 28.

40.

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI.

Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c.

PMID:
19434004
41.

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.

Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, Munster PN.

Clin Cancer Res. 2009 Apr 1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24.

42.

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R.

J Clin Oncol. 2008 Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24.

43.

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S.

J Clin Oncol. 2008 Nov 10;26(32):5198-203. doi: 10.1200/JCO.2008.17.2064. Epub 2008 Sep 29.

44.

State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.

Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK.

Cancer. 2008 Oct 1;113(7 Suppl):1728-43. doi: 10.1002/cncr.23643. Review. No abstract available.

45.

Activated stat-3 in melanoma.

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI.

Cancer Control. 2008 Jul;15(3):196-201.

PMID:
18596671
46.

Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios.

Zager JS, Daud AI.

Cancer Control. 2008 Jul;15(3):192-4. No abstract available.

PMID:
18596670
47.

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D.

J Clin Oncol. 2008 Jul 1;26(19):3235-41. doi: 10.1200/JCO.2007.13.9048.

PMID:
18591558
48.

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI.

Clin Cancer Res. 2007 Oct 1;13(19):5855-61.

49.

Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.

Homsi J, Daud AI.

Cancer Control. 2007 Jul;14(3):285-94. Review.

PMID:
17615535
50.

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI.

Cancer Control. 2006 Jul;13(3):211-7.

PMID:
16885917

Supplemental Content

Support Center